Toll Free: 1-888-928-9744

Almirall, S.A. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Almirall, S.A. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Almirall, S.A. - Product Pipeline Review - 2015', provides an overview of the Almirall, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Almirall, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Almirall, S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Almirall, S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Almirall, S.A.'s pipeline products

Reason to Buy

- Evaluate Almirall, S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Almirall, S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Almirall, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Almirall, S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Almirall, S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Almirall, S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Almirall, S.A. Snapshot 5 Almirall, S.A. Overview 5 Key Information 5 Key Facts 5 Almirall, S.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Almirall, S.A. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Almirall, S.A. - Pipeline Products Glance 13 Almirall, S.A. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Almirall, S.A. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Almirall, S.A. - Drug Profiles 16 cinitapride 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 dimethyl fumarate 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 (betamethasone dipropionate + bexarotene) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 tazarotene 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Almirall, S.A. - Pipeline Analysis 20 Almirall, S.A. - Pipeline Products by Target 20 Almirall, S.A. - Pipeline Products by Route of Administration 21 Almirall, S.A. - Pipeline Products by Molecule Type 22 Almirall, S.A. - Pipeline Products by Mechanism of Action 23 Almirall, S.A. - Recent Pipeline Updates 24 Almirall, S.A. - Dormant Projects 25 Almirall, S.A. - Discontinued Pipeline Products 26 Discontinued Pipeline Product Profiles 26 LAS-37779 26 LAS-41007 26 Almirall, S.A. - Company Statement 27 Almirall, S.A. - Locations And Subsidiaries 28 Head Office 28 Other Locations & Subsidiaries 28 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31
List of Tables
Almirall, S.A., Key Information 5 Almirall, S.A., Key Facts 5 Almirall, S.A. - Pipeline by Indication, 2015 7 Almirall, S.A. - Pipeline by Stage of Development, 2015 8 Almirall, S.A. - Monotherapy Products in Pipeline, 2015 9 Almirall, S.A. - Combination Treatment Modalities in Pipeline, 2015 10 Almirall, S.A. - Out-Licensed Products in Pipeline, 2015 11 Almirall, S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 12 Almirall, S.A. - Pre-Registration, 2015 13 Almirall, S.A. - Phase III, 2015 14 Almirall, S.A. - Phase II, 2015 15 Almirall, S.A. - Pipeline by Target, 2015 20 Almirall, S.A. - Pipeline by Route of Administration, 2015 21 Almirall, S.A. - Pipeline by Molecule Type, 2015 22 Almirall, S.A. - Pipeline Products by Mechanism of Action, 2015 23 Almirall, S.A. - Recent Pipeline Updates, 2015 24 Almirall, S.A. - Dormant Developmental Projects,2015 25 Almirall, S.A. - Discontinued Pipeline Products, 2015 26 Almirall, S.A., Subsidiaries 28



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify